. 2020 Apr 21;8(2):192. doi: 10.3390/vaccines8020192

Table 3.

p27 antibody concentrations in RSV infected HCT adults who shed RSV <14 days and ≥14 days.

p27 Antibody Test	Serum	<14 Days (n = 17)	Fold Change	≥14 Days (n = 16)	Fold Change	p-Value ^b
Serum IgG ELISA	Acute	405.0 (174.3, 946.4)^a	1.1	422.0 (203.6, 946.0)	2.2	0.942
Serum IgG ELISA	Convalescent	461.6 (24.7, 922.0)	1.1	944.7 (439.5, 1920.2)	2.2	0.183
Serum IgA ELISA	Acute	43.8 (14.6, 105.8)	0.6	30.3 (11.1, 60.1)	1.6	0.587
Serum IgA ELISA	Convalescent	24.4 (6.1, 74.1)	0.6	48.2 (15.9, 108.0)	1.6	0.413
Serum P₂₇CA	Acute	484.5 (118.6, 1833.0)	9.8	166.1 (52.1, 639.4)	6.8	0.271
Serum P₂₇CA	Convalescent	4756.7 (1593.3, 10,822.9)	9.8	1122.2 (318.5, 3027.5)	6.8	0.071
Mucosal IgG ELISA	Acute	2.9 (0.4, 21.1)	0.2	2.6 (0.4, 13.6)	0.9	0.935
Mucosal IgG ELISA	Convalescent	0.7 (0.1, 4.1)	0.2	2.3 (0.4, 12.3)	0.9	0.574
Mucosal IgA ELISA	Acute	1.7 (0.5, 6.0)	0.4	3.5 (0.9, 11.2)	0.5	0.430
Mucosal IgA ELISA	Convalescent	0.7 (0.2, 2.5)	0.4	1.6 (0.4, 5.2)	0.5	0.772
Mucosal P₂₇CA	Acute	197.5 (71.0, 563.1)	1.0	106.4 (46.0, 283.0)	0.8	0.378
Mucosal P₂₇CA	Convalescent	200.1 (84.7, 470.9)	1.0	88.3 (41.2, 213.7)	0.8	0.195

^a Geometric mean concentration (ng/mL) for serum and mucosal antibodies (95% Confidence Interval) in RSV infected HCT adults. ^b Two-sample t test for differences in means of antibody concentration (log2 ng/mL) in HCT adults who shed RSV <14 days and ≥14 days.